SCHEMBL23685489

SCHEMBL23685489

CC(C)(C)OC(=O)CCN(CCCO)C(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.53
PAX8 Q06710 1/20 0.53
L3MBTL1 Q9Y468 5/20 0.43
ALDH1A1 P00352 3/20 0.39
SYK P43405 1/20 0.38
MAPK1 P28482 1/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
ALOX5 P09917 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
ABCB1 P08183 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22899929 0.95 CCR6 (0.53) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL1555285 0.93 CCR6 (0.49) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL23685487 0.87 CCR6 (0.47) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL6338766 0.86 CCR6 (0.50) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL20089220 0.85 L3MBTL1 (0.46) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL23685470 0.85 ALDH1A1 (0.48) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL9766179 0.85 CCR6 (0.53) CCR6PAX8SYKLMNASMN1; SMN2
SCHEMBL1569283 0.84 ALDH1A1 (0.43) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL25257598 0.84 CCR6 (0.44) CCR6PAX8L3MBTL1ALDH1A1SYK
SCHEMBL6341393 0.84 CCR6 (0.48) CCR6PAX8L3MBTL1ALDH1A1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141981-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) 2023-05-11 US disclosed
US-20230141981-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) 2023-05-11 US disclosed
WO-2021150792-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS MICURX PHARMACEUTICALS, INC. (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141981-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS GLS, ATP6V1B1, KRAS CCR6 1061/4885PAX8 818/4885L3MBTL1 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.